Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

The circulating exosomal microRNAs related to albuminuria in patients with diabetic nephropathy

Kim H., Bae YU., Jeon JS., Noh H., Park HK., Byun DW.

Prospective Study with a reported sample of 74 on Chronic Kidney Disease, published in J Transl Med (2019) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Transl Med (2019)
Reported sample size
74
Source database
Europe PMC
PMID
31331349
PMCID
PMC6647278
DOI
10.1186/s12967-019-1983-3
Citations
61

Abstract (original English)

Background Diabetic nephropathy (DN) is associated with high risk of cardiovascular disease and mortality. Exosomal microRNAs (miRNAs) regulate gene expression in a variety of tissues and play important roles in the pathology of various diseases. We hypothesized that the exosomal miRNA profile would differ between DN patients and patients without nephropathy. Methods We prospectively enrolled 74 participants, including healthy volunteers (HVs), diabetic patients without nephropathy, and those with DN. The serum exosomal miRNA profiles of participants were examined using RNA sequencing. Results The expression levels of 107 miRNAs differed between HVs and patients without DN, whereas the expression levels of 95 miRNAs differed between HVs and patients with DN. Among these miRNAs, we found 7 miRNAs (miR-1246, miR-642a-3p, let-7c-5p, miR-1255b-5p, let-7i-3p, miR-5010-5p, miR-150-3p) that were uniquely up-regulated in DN patients compared to HVs, and miR-4449 that was highly expressed in DN patients compared to patients without DN. A pathway analysis revealed that these eight miRNAs are likely involved in MAPK signaling, integrin function in angiogenesis, and regulation of the AP-1 transcription factor. Moreover, they were all significantly correlated with the degree of albuminuria. Conclusions Patients with DN have a different serum exosomal miRNA profile compared to HVs. These miR

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansDiabetic NephropathiesAlbuminuriaDNA, ComplementaryTreatment OutcomeProspective StudiesGene Expression ProfilingSequence Analysis, RNAGene LibraryAdult

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research